Skip to main content

S1.

Clinical performance of physician- and self-collected careHPV testing in primary and triage screening strategies, stratified by age, for CIN2+ detection among 2,337 women

Primary screening Triage strategy Age (year) CIN2+ (N=68) % (95% CI) Colposcopy per CIN2+ (N)
Sensitivity Specificity PPV NPV Youden’s index
HPV, human papillomavirus; CIN2+, cervical intraepithelial neoplasia grade 2 or worse; RLU/CO, relative light units/cutoff; HC2, Hybrid Capture 2; ASC-US+, atypical squamous cells of undetermined significance or worse; VIA, visual inspection with acetic acid; 95% CI, 95% confidence interval; PPV, positive predictive value; NPV, negative predictive value.
Physician-careHPV ≥1.0 RLU/CO ASC-US+ 30 to 44 32 82.1
(67.3–91.0)
96.1
(94.9–97.0)
38.6
(28.8–49.3)
99.4
(98.9–99.7)
78.2 2.6
45 to 54 23 79.3
(61.6–90.2)
93.4
(91.7–94.8)
26.7
(18.5–36.9)
99.3
(98.6–99.7)
72.7 3.7
VIA 30 to 44 13 33.3
(20.6–49.0)
99.0
(98.3–99.4)
50.0
(32.1–67.9)
98.0
(97.1–98.7)
32.3 2.0
45 to 54 8 27.6
(14.7–45.7)
99.4
(98.6–99.7)
57.1
(32.6–78.6)
97.8
(96.7–98.6)
27.0 1.8
Self-careHPV ≥1.0 RLU/CO ASC-US+ 30 to 44 29 74.4
(58.9–85.4)
96.9
(95.8–97.7)
41.4
(30.6–53.1)
99.2
(98.6–99.6)
71.2 2.4
45 to 54 16 55.2
(37.5–71.6)
95.7
(94.2–96.8)
28.1
(18.1–40.8)
98.6
(97.6–99.2)
50.9 3.6
VIA 30 to 44 13 33.3
(20.6–49.0)
99.0
(98.3–99.4)
50.0
(32.1–67.9)
98.0
(97.1–98.7)
32.3 2.0
45 to 54 5 17.2
(7.6–34.5)
99.5
(99.6–100)
50.0
(23.7–76.3)
97.5
(96.4–98.3)
16.7 2.0
Physician-HC2 ≥1.0 RLU/CO AS-CUS+ 30 to 44 37 94.9
(83.1–98.6)
95.2
(93.9–96.2)
37.0
(28.2–46.8)
99.8
(99.4–100)
90.1 2.7
45 to 54 26 89.7
(73.6–96.4)
93.2
(91.4–94.6)
28.6
(20.3–38.6)
99.7
(99.0–99.9)
82.9 3.5
VIA 30 to 44 16 41.0
(27.1–56.6)
98.9
(98.1–99.3)
51.6
(34.8–68.0)
98.3
(97.4–98.8)
39.9 1.9
45 to 54 10 34.5
(19.9–52.7)
99.3
(98.5–99.6)
58.8
(36.0–78.4)
98.0
(97.0–98.4)
33.8 1.7